Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1007/s10456-011-9221-5.

Title:
VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway | Angiogenesis
Description:
Vascular angiogenesis is regulated by a number of cytokines of which vascular endothelial growth factor (VEGF)-A/and its receptor vascular endothelial growth factor receptor 2 (VEGFR2) play an indisputable role. Similarly lymphangiogenesis is regulated by VEGF-C and its receptor VEGFR3. Currently for treating vasculogenesis diseases such as proliferative retinopathies and cancer, a number of anti-VEGF-A therapies are approved for clinical use. Although clinical efficacies achieved are remarkable, they are found to be transitory in nature, followed by restoration of anti-VEGF therapy resistant angiogenesis. Recently the regulatory role of VEGF-C in initiating and potentiating neo-angiogenesis has been uncovered. Although the interactive nature of VEGF-A and C is known, the dynamics of their expression under knockdown conditions is yet to be established. Here in this study we have utilized siRNA to knockdown both VEGF-A and C either independently or in combination. Analysis of VEGF-A and C expression (only in cancer cell lines MCF7, A549 and H460 but not in the ocular cell line RPE19) has shown enhanced expression levels of VEGF-C with increase in knockdown of VEGF-A. However, VEGF-C knockdown has resulted in decreased expression levels of VEGF-A both in RPE19 and MCF7 cells in a dose dependent manner. In addition, VEGF-C knockdown also resulted in decreased expression of RhoA. Further, knockdown studies of RhoA even with supplementation of VEGF-C or A has resulted in decreased endothelial cell proliferation and stress fiber formation, indicating that VEGF-C does promote angiogenesis via RhoA mediated pathway.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {๐Ÿ“š}

  • Education
  • Science
  • Social Networks

Content Management System {๐Ÿ“}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {๐Ÿ“ˆ}

What is the average monthly size of link.springer.com audience?

๐ŸŒ  Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {๐Ÿ’ธ}

We're unsure how the site profits.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {๐Ÿ”}

article, google, scholar, angiogenesis, pubmed, cas, cancer, endothelial, vegfc, vascular, growth, factor, cell, vegfa, expression, kumar, nature, knockdown, tumor, promotes, rhoa, receptor, therapy, sci, privacy, cookies, content, regulates, cells, mediated, lymphangiogenesis, access, res, life, information, publish, research, search, chile, ray, addepalli, role, conditions, human, sciences, data, log, journal, ocular, pathway,

Topics {โœ’๏ธ}

venkata ramanaย &ย vikram rajagopal month download article/chapter anti-angiogenic factor pedf rhoa/rho kinase signaling article angiogenesis aims full article pdf reliance life sciences human tumor angiogenesis intralymphatic tumor growth privacy choices/manage cookies gene ther 17 rhoa mediated pathway anti angiogenic therapy retinalvascular endothelial cells vascular network formation rho activity critically elevated cell invasion potentiating neo-angiogenesis /vegf receptor system rho signaling prostate tumor regression young diabetic patients streptozotocin diabetic rat vikram rajagopal related subjects promotes tumor lymphangiogenesis european economic area stress fiber formation quantitative vitreaous fluorophotometry measuring early breakdown blood-tretinal barrier hull-campbell ne cyclin-dependent kinases syndecan-4 signals cooperatively actin stress fibers authors gratefully acknowledge thane-belapur road rnai mediated knockdown primary breast cancer dose dependent manner freeze fracture studies pre-malignant conditions differentially regulates vegf electronic supplementary material decreased expression levels conditions privacy policy accepting optional cookies treating vasculogenesis diseases clinical efficacies achieved author information authors

Questions {โ“}

  • Folkman J (2007) Angiogenesis: an organizing principle for drug discovery?

Schema {๐Ÿ—บ๏ธ}

WebPage:
      mainEntity:
         headline:VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway
         description:Vascular angiogenesis is regulated by a number of cytokines of which vascular endothelial growth factor (VEGF)-A/and its receptor vascular endothelial growth factor receptor 2 (VEGFR2) play an indisputable role. Similarly lymphangiogenesis is regulated by VEGF-C and its receptor VEGFR3. Currently for treating vasculogenesis diseases such as proliferative retinopathies and cancer, a number of anti-VEGF-A therapies are approved for clinical use. Although clinical efficacies achieved are remarkable, they are found to be transitory in nature, followed by restoration of anti-VEGF therapy resistant angiogenesis. Recently the regulatory role of VEGF-C in initiating and potentiating neo-angiogenesis has been uncovered. Although the interactive nature of VEGF-A and C is known, the dynamics of their expression under knockdown conditions is yet to be established. Here in this study we have utilized siRNA to knockdown both VEGF-A and C either independently or in combination. Analysis of VEGF-A and C expression (only in cancer cell lines MCF7, A549 and H460 but not in the ocular cell line RPE19) has shown enhanced expression levels of VEGF-C with increase in knockdown of VEGF-A. However, VEGF-C knockdown has resulted in decreased expression levels of VEGF-A both in RPE19 and MCF7 cells in a dose dependent manner. In addition, VEGF-C knockdown also resulted in decreased expression of RhoA. Further, knockdown studies of RhoA even with supplementation of VEGF-C or A has resulted in decreased endothelial cell proliferation and stress fiber formation, indicating that VEGF-C does promote angiogenesis via RhoA mediated pathway.
         datePublished:2011-06-23T00:00:00Z
         dateModified:2011-06-23T00:00:00Z
         pageStart:371
         pageEnd:380
         sameAs:https://doi.org/10.1007/s10456-011-9221-5
         keywords:
            VEGF-C
            VEGF-A
            siRNA
            RhoA
            Cancer
            Cancer Research
            Biomedicine
            general
            Cell Biology
            Cardiology
            Ophthalmology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig6_HTML.gif
         isPartOf:
            name:Angiogenesis
            issn:
               1573-7209
               0969-6970
            volumeNumber:14
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Bharat Kumar
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shailaja A. Chile
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kriti B. Ray
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:G. E. C. Vidyadhar Reddy
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Murali K. Addepalli
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. S. Manoj Kumar
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Venkata Ramana
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vikram Rajagopal
               affiliation:
                     name:Dhirubhai Ambani Life Sciences Center (DALC)
                     address:
                        name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:VEGF-C differentially regulates VEGF-A expression in ocular and cancer cells; promotes angiogenesis via RhoA mediated pathway
      description:Vascular angiogenesis is regulated by a number of cytokines of which vascular endothelial growth factor (VEGF)-A/and its receptor vascular endothelial growth factor receptor 2 (VEGFR2) play an indisputable role. Similarly lymphangiogenesis is regulated by VEGF-C and its receptor VEGFR3. Currently for treating vasculogenesis diseases such as proliferative retinopathies and cancer, a number of anti-VEGF-A therapies are approved for clinical use. Although clinical efficacies achieved are remarkable, they are found to be transitory in nature, followed by restoration of anti-VEGF therapy resistant angiogenesis. Recently the regulatory role of VEGF-C in initiating and potentiating neo-angiogenesis has been uncovered. Although the interactive nature of VEGF-A and C is known, the dynamics of their expression under knockdown conditions is yet to be established. Here in this study we have utilized siRNA to knockdown both VEGF-A and C either independently or in combination. Analysis of VEGF-A and C expression (only in cancer cell lines MCF7, A549 and H460 but not in the ocular cell line RPE19) has shown enhanced expression levels of VEGF-C with increase in knockdown of VEGF-A. However, VEGF-C knockdown has resulted in decreased expression levels of VEGF-A both in RPE19 and MCF7 cells in a dose dependent manner. In addition, VEGF-C knockdown also resulted in decreased expression of RhoA. Further, knockdown studies of RhoA even with supplementation of VEGF-C or A has resulted in decreased endothelial cell proliferation and stress fiber formation, indicating that VEGF-C does promote angiogenesis via RhoA mediated pathway.
      datePublished:2011-06-23T00:00:00Z
      dateModified:2011-06-23T00:00:00Z
      pageStart:371
      pageEnd:380
      sameAs:https://doi.org/10.1007/s10456-011-9221-5
      keywords:
         VEGF-C
         VEGF-A
         siRNA
         RhoA
         Cancer
         Cancer Research
         Biomedicine
         general
         Cell Biology
         Cardiology
         Ophthalmology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10456-011-9221-5/MediaObjects/10456_2011_9221_Fig6_HTML.gif
      isPartOf:
         name:Angiogenesis
         issn:
            1573-7209
            0969-6970
         volumeNumber:14
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Bharat Kumar
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shailaja A. Chile
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kriti B. Ray
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:G. E. C. Vidyadhar Reddy
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Murali K. Addepalli
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. S. Manoj Kumar
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Venkata Ramana
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vikram Rajagopal
            affiliation:
                  name:Dhirubhai Ambani Life Sciences Center (DALC)
                  address:
                     name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Angiogenesis
      issn:
         1573-7209
         0969-6970
      volumeNumber:14
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
      name:Dhirubhai Ambani Life Sciences Center (DALC)
      address:
         name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Bharat Kumar
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:Shailaja A. Chile
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:Kriti B. Ray
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:G. E. C. Vidyadhar Reddy
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:Murali K. Addepalli
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:A. S. Manoj Kumar
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:Venkata Ramana
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      name:Vikram Rajagopal
      affiliation:
            name:Dhirubhai Ambani Life Sciences Center (DALC)
            address:
               name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
      name:Therapeutics Protein Group, Reliance Life Sciences Pvt. Ltd., Dhirubhai Ambani Life Sciences Center (DALC), Navi Mumbai, India
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {๐Ÿ”—}(121)

Analytics and Tracking {๐Ÿ“Š}

  • Google Tag Manager

Libraries {๐Ÿ“š}

  • Clipboard.js
  • Prism.js

CDN Services {๐Ÿ“ฆ}

  • Crossref

3.89s.